TRU Capital Raising August 2018

NZX and Media Release 31 August 2018
TRUSCREEN ANNOUNCES CAPITAL RAISING TO FUND COMMERCIAL OPPORTUNITIES
Cervical cancer technology company, TruScreen Limited (NZAX:TRU) advises that it is undertaking a
capital raising to strengthen its balance sheet and fund commercial growth.
The company, which is well progressed in its commercial realisation pathway, has identified a
number of immediate opportunities to drive sales and position the company for continued growth.
The new capital will be used to strengthen the balance sheet, fund sales and marketing initiatives,
expand manufacturing capabilities and continue improvement to the device’s performance.
The capital raising comprises a $1.5 million Placement to institutional and other select investors at
21 cents per share, which was completed on 31 August 2018 and a Share Purchase Plan (SPP), which
will be available to existing retail shareholders of the company, on the same terms and pricing as the
Placement. Dates for the SPP will be announced shortly and relevant documents will be sent to
shareholders.
TruScreen has the world’s only EC certified, real time, objective primary screening device for cervical
cancer. The company has made significant progress in the last year and is now reaching a major
turning point in its commercial pathway.
Chairman of TruScreen, Mr Robert Hunter, said: “Our company is well progressed in its commercial
realisation pathway. There is growing awareness and demand for our TruScreen cervical cancer
screening technology; sales are growing rapidly, particularly in China; our new manufacturing facility
is now online; and the Board has been refreshed over the last year, with the appointment of new
Directors with relevant industry and market knowledge and expertise.
There are a number of immediate commercial opportunities available to us and the capital raise will
ensure we have the resources and capacity to progress with these. We are delighted with the
support we received for the Placement from our large investors. The SPP will allow our retail
shareholders an equal opportunity to participate in this capital raising.”
In particular, funds will be used to:
• Expand commercial growth in China, Africa, India and Latin America;
• Fund clinical and familiarisation trials as required for product improvement and acceptance
in government programs;
• Expand manufacturing facilities and supply capabilities;
• Build-up inventory; and
• Continued product refinement.
Placement
The placement was undertaken with institutional and other select investors subscribing for
7,142,856 shares at 21 cents per share. Settlement and allotment of the new shares is expected to
occur on 5 September 2018.

Share Purchase Plan
Existing retail shareholders of TruScreen will be invited to subscribe for new shares under a Share
Purchase Plan. The subscription price will be the same as that for the private placement, being 21
cents per share. The record date for determining entitlements to participate in the Share Purchase
Plan and other key dates will be announced shortly.
For questions about this Offer, shareholders should consult their broker, solicitor, accountant,
financial adviser, or other professional adviser.
ENDS
For more information visit www.truscreen.com or contact Martin Dillon, TruScreen Chief Executive Officer,
email: martindillon@truscreen.com
About TruScreen:
TruScreen’s real time cervical cancer
technology utilises a digital wand which is
placed on the surface of the cervix to measure
electrical and optical signals from the
surrounding tissue. A sophisticated proprietary
algorithm framework distinguishes between
normal and abnormal (cancerous and
precancerous) tissue to identify precancerous
change, or cervical intraepithelial neoplasia
(CIN). A Single Use Sensor (SUS) is used for
each patient to protect against cross-infection.